Friday, 23 Oct 2026
Empowering Chinese Pharma’s Global Expansion
Contact US
Home
About US
Policy Hub
Categories
Drug
Company
Deals
Policy / Regulatory
Medical Device
R&D
Legal / IP
Digital
Privacy Policy
Contact US
My News
Cancer
Clinical trial approval / initiation
Product approvals
Clinical trial results
Finance
ADC / XDC
Finanical Reports
Biotech
Market approval filings
PD-1/L1
Read History
Search
Pages
Home
Blog Index
POLICY HUB
Contact Us
Personalized
Read History
Categories
Company
Drug
Policy / Regulatory
Medical Device
R&D
Digital
Legal / IP
Deals
Have an existing account?
Sign In
Follow US
Fineline Cube
Follow:
14724
Articles
Company
Drug
Haixi Pharma Advances HXP056 to Phase II – Oral Multi‑Selective Therapy for Wet AMD and Hemorrhagic Retinal Diseases
March 25, 2026
Company
Drug
IASO Bio Wins Japan PMDA Approval for Fucaso CAR‑T – BCMA Therapy Enters Phase III in Relapsed/Refractory Multiple Myeloma
March 25, 2026
Company
Kelun‑Biotech Reports 2025 Revenue RMB 2.06 Billion – Four Drugs Commercialized, 30+ Pipeline Assets Drive Diversification
March 25, 2026
Company
Drug
Hope Medicine Doses First Patient in HMI-115 Phase III – First-in-Class Non-Hormonal Endometriosis Therapy Advances in China
March 25, 2026
Company
Drug
Kelun‑Biotech’s SKB103 Wins NMPA Approval – Novel TAA‑PD‑L1 Bispecific ADC Enters Clinical Trials for Advanced Solid Tumors
March 25, 2026
Company
Fosun Pharma Reports 2025 Results – Innovative Drug Revenue Surges 30% to RMB 9.9 Billion, Overseas Sales Hit RMB 13 Billion
March 24, 2026
Company
Drug
Alphamab Oncology Doses First Patient in Phase III KN026 Study – Bispecific HER2 Antibody Targets Adjuvant Breast Cancer
March 24, 2026
Others
Gilead to Acquire Ouro Medicines for $2.175 Billion – Keymed Biosciences Secures $320 Million from CM336 TCE Deal
March 24, 2026
Company
Drug
Shenzhen Salubris Wins NMPA Approval for SAL0150 – Oral Long-Acting Diabetes/Obesity Drug Targets Weekly Dosing Regimen
March 24, 2026
Company
Roche Opens Institute of Human Biology – CHF 1.4 Billion Basel Investment Targets Human Model Systems for Drug Discovery Revolution
March 24, 2026
Company
Deals
Kali Therapeutics Licenses KT501 to Sanofi – $1.23B Deal for Trispecific T-Cell Engager Targets Autoimmune Diseases
March 24, 2026
Company
Drug
GSK’s Risvutatug Rezetecan Wins Japan ODD – B7-H3 ADC Targets Small-Cell Lung Cancer with Phase 1 Durable Responses
March 24, 2026
1
2
…
161
162
163
164
165
…
1,226
1,227
Welcome to Fineline Cube!
Username or Email Address
Password
Remember me
Lost your password?